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Since anthracycline-induced cardiotoxicity (AIC), a complication of anthracycline-based chemotherapies, is thought to involve
iron, concerns exist about using iron for anaemia treatment in anthracycline-receiving cancer patients. Lis study evaluated how
intravenous ferric carboxymaltose (FCM) modulates the inXuence of iron de8ciency anaemia (IDA) and doxorubicin (3–5mg
per kg body weight [BW]) on oxidative/nitrosative stress, inXammation, and cardiorenal function in spontaneously hypertensive
stroke-prone (SHR-SP) rats. FCM was given as repeated small or single total dose (15mg iron per kg BW), either concurrent
with or three days a_er doxorubicin. IDA (a_er dietary iron restriction) induced cardiac and renal oxidative stress (markers
included malondialdehyde, catalase, Cu,Zn-superoxide dismutase, and glutathione peroxidase), nitrosative stress (inducible nitric
oxide synthase and nitrotyrosine), inXammation (tumour necrosis factor-alpha and interleukin-6), and functional/morphological
abnormalities (le_ ventricle end-diastolic and end-systolic diameter, fractional shortening, density of cardiomyocytes and
capillaries, caveolin-1 expression, creatinine clearance, and urine neutrophil gelatinase-associated lipocalin) that were aggravated
by doxorubicin. Notably, iron treatment with FCMdid not exacerbate but attenuated the cardiorenal ecects of IDA and doxorubicin
independent of the iron dosing regimen. Le results of this model suggest that intravenous FCM can be used concomitantly with
an anthracycline-based chemotherapy without increasing signs of AIC.
1. Introduction
Cytotoxic cancer treatments frequently include anthracy-
clines [1]. However, their use is associated with a risk of
anthracycline-induced cardiotoxicity (AIC) leading to acute
transient arrhythmias, chronic cardiomyopathy, and heart
failure [2]. It is hypothesised that AIC results from anthracy-
cline-mediated radical reactions and production of reactive
oxygen species (ROS), which may involve anthracycline-iron
complexes [3–5].
Considering that anaemia and iron de8ciency (ID) are
frequent complications in cancer patients [6, 7] and require
iron supplementation [8, 9], clinicians are concerned that
concomitant use of anthracyclines and iron might increase
AIC. However, anaemia and ID should be treated since
anaemia is associated with fatigue and impaired response
to cancer treatment and survival [10–12]. Furthermore,
even ID alone can increase oxidative/nitrosative stress in
the heart [13]. Among available iron treatments, oral iron
salts are o_en poorly tolerated whereas intravenous (i.v.)
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Table 1: Haematological, functional, and oxidative/nitrosative stress and inXammatory markers according to iron diet and DOX treatment.
Group
A B C D E F
Parameter
Iron diet LID LID LID LID ND ND
DOX dose (mg/kg BW) 3 4 5 0 4 0
Hb (g/dL) 8.9 ± 0.5 8.6 ± 0.4 8.3 ± 0.5 10.3 ± 0.5† 13.4 ± 0.7‡ 17.1 ± 0.5∗
TSAT (%) 13.8 ± 2.3 11.9 ± 9.0 10.9 ± 4.3 12.7 ± 2.0 36.4 ± 3.0‡ 41.8 ± 4.1‡
LVDD (mm) 8.61 ± 0.12 8.70 ± 0.14‖ 9.02 ± 0.13∗ 8.30 ± 0.12 8.28 ± 0.14 7.80 ± 0.10∗
LVSD (mm) 5.60 ± 0.11 6.00 ± 0.10‖ 6.34 ± 0.11∗ 5.10 ± 0.10 5.20 ± 0.11 4.50 ± 0.12∗
FS (%) 34.9 ± 1.7 31.0 ± 1.3‖ 29.6 ± 1.4∗ 38.6 ± 1.4† 37.2 ± 1.6† 42.3 ± 1.9∗
Caveolin-1 (%/area) 18.2 ± 2.0 15.6 ± 1.8‖ 14.9 ± 2.1‖ 23.1 ± 2.2† 24.7 ± 3.0† 32.3 ± 2.7∗
Cu,Zn-SOD (U/mg protein) 33.5 ± 2.3 37.2 ± 2.6‖ 40.1 ± 2.8§ 24.7 ± 1.9† 28.4 ± 2.1† 18.9 ± 1.5∗
GPx (U/mg protein) 423.2 ± 22.7 460.5 ± 26.4‖ 488.4 ± 30.1§ 376.9 ± 32.4† 389.4 ± 27.4† 264.3 ± 20.6∗
MDA (nmol/mg protein) 3.4 ± 0.1 3.7 ± 0.2‖ 4.0 ± 0.2§ 2.8 ± 0.3† 3.0 ± 0.2† 1.9 ± 0.2∗
GSH :GSSG ratio 3.0 ± 0.2 2.7 ± 0.1‖ 2.3 ± 0.3§ 4.0 ± 0.3† 3.8 ± 0.2† 4.7 ± 0.3∗
Nitrotyrosine (%/area) 24.1 ± 3.2 28.9 ± 3.7‖ 34.8 ± 3.0§ 14.9 ± 2.6† 16.7 ± 2.1† 12.2 ± 2.0∗
TNF-훼 (%/area) 18.7 ± 2.0 19.2 ± 1.6 20.1 ± 2.3 14.8 ± 1.7† 15.1 ± 1.9† 12.1 ± 2.0∗
Data presented as mean ± SD. LID: low iron diet; ND: normal diet; DOX: doxorubicin; Hb: hemoglobin; TSAT: transferrin saturation; LVDD: le_
ventricular end-diastolic diameter; LVSD: le_ ventricular end-systolic diameter; FS: fractional shortening; Cu,Zn-SOD: copper-zinc superoxide dismutase;
GPx: glutathione peroxidase; MDA: malondialdehyde; GSH :GSSG: reduced glutathione : oxidised glutathione; TNF-훼: tumour necrosis factor alpha.
∗푃 < 0.05 versus all groups; †푃 < 0.05 versus A, B, and C; ‡푃 < 0.01 versus A, B, C, and D; §푃 < 0.05 versus A and B; ‖푃 < 0.05 versus A.
iron preparations are well tolerated at recommended doses
and improve haematological response to erythropoiesis-
stimulating agents [9, 14].
Le primary objective of this study was to evaluate
whether i.v. iron treatment (ferric carboxymaltose, FCM,
Vifor Pharma) modulates doxorubicin- (DOX-) induced
AIC. For this purpose, we established a model of DOX-
induced cardiotoxicity in spontaneously hypertensive stroke-
prone (SHR-SP) rats with iron de8ciency anaemia (IDA).
Since DOX is also nephrotoxic [15, 16], kidney assess-
ments were performed in parallel (see Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2014/570241).
2. Materials and Methods
2.1. Animals. All experiments were approved by the Hospital
Aleman Animal Care and the Teaching and Research Com-
mittee and performed in accordance with the NIH Guide
for the Care and Use of Laboratory Animals. Lree-week-
oldmale SHR-SP rats (Charles River Laboratories, USA)were
acclimatized in a temperature-controlled room (22 ± 2∘C)
with free access to tap water and normal diet (iron content
250 ppm, Provimi-Kliba, Switzerland) ad libitum. During the
study, animals received normal diet (ND) or low iron diet
(LID, 7 ppm iron) as speci8ed in Table 1. DOX was given as
intraperitoneal (i.p.) and FCM as i.v. injection (both 0.5mL).
2.2. Treatment
2.2.1. Model 1. A_er 4 weeks of acclimatization, 48 SHR-SP
rats were randomized into six groups (푛 = 8/group). Groups
A–D were kept on LID for the entire study while Groups E-F
received ND. A_er 12 weeks, Groups A–C received 6 weekly
DOX injections of 3, 4, or 5mg/kg BW, respectively. Group E
received 6 weekly DOX injections of 4mg/kg BW. Groups D
and F received saline solution.
2.2.2. Model 2. A_er 3 weeks of acclimatization, 64 SHR-
SP rats were randomized into eight groups (푛 = 8/group).
Groups 1–6 were fed with LID while Groups 7 and 8 were fed
with ND. A_er 7 weeks, Groups 1–5 and Group 8 received 6
weekly DOX injections at 4mg/kg BW. In addition, starting
at the second weekly DOX injection, Groups 1 and 2 received
5 weekly FCM injections at 3mg iron/kg BW concurrent
with or 3 days a_er DOX treatment, respectively, while
Groups 3 and 4 received a single FCM injection at 15mg
iron/kg BW concurrent with or 3 days a_er the second DOX
injection, respectively. Group 8 received a single injection of
FCM at 15mg iron/kg BW concurrent with the second DOX
injection. Group 5 received saline injections concurrent with
DOX and Groups 6 and 7 received 6 weekly i.p. and 5 weekly
i.v. saline injections, respectively.
Two weeks a_er the last DOX or saline injection (end of
study), anaesthetized rats were euthanized by subtotal exsan-
guination, and tissue samples were taken for histological
assessments.
2.3. Blood Pressure and Echocardiography. At study end,
systolic and diastolic blood pressure (SBP and DBP) were
measured in nonanaesthetized rats as described [17]. Trans-
thoracic echocardiograms and assessment of interventricular
septum (IVS) and le_ ventricular posterior wall (LVPW)
diastolic thickness, le_ ventricular end-diastolic and end-
systolic diameter (LVDD, LVSD), and fractional shortening
(FS) were performed as described previously [18].
2.4. Laboratory Parameters. Blood hemoglobin (Hb) and
serum iron were measured using routine blood analyzers
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(Hb: HemoCue, Sweden; SYSMEX XT 1800i, Japan; iron:
Roche Diagnostics Autoanalyser Modular-P800, Germany).
Serum transferrin was determined by radial immunodif-
fusion (Biocienti8ca, Argentina) and transferrin saturation
(TSAT) was calculated as described previously [19]. Urine
neutrophil gelatinase-associated lipocalin (NGAL) was mea-
sured by ELISA (BioPorto Diagnostics, Denmark).
2.5. Biochemical Assessment of Oxidative Stress in Heart
Samples. Liobarbituric acid reactive substances (TBARS),
malondialdehyde (MDA), and glutathione, as well as the
activities of catalase, Cu,Zn superoxide dismutase (Cu,Zn-
SOD), and glutathione peroxidase (GPx) were quanti8ed
in tissue homogenates of the saline-perfused heart (le_
ventricular free wall [LVFW], le_ ventricular septum [LVS],
and right ventricle [RV]) as previously described [20–23].
2.6. Histology. Lree-micron sections of LVFW, LVS, and RV
were 8xed in phosphate-bucered, 10% formaldehyde (pH =
7.2), embedded in paravn, and stained with Sirius Red
[24]. Histomorphometric evaluations (width and density of
cardiomyocytes, density of capillaries (vessels <8휇m), and
ratio cardiomyocytes/capillaries) were performed at ×400
magni8cation using a Nikon E400 light microscope and an
image analyser (Image-Pro Plus 4.5 for Windows, Media
Cybernetics LP, USA).
Immunohistochemistry was performed with antibodies
against tumour necrosis factor-alpha (TNF-훼, AF-510-NA,
R&DSystems,USA), interleukin- (IL-) 6 (sc-1265, Santa Cruz
Biotechnology, USA), inducible nitric oxide synthase (iNOS,
sc-651, Santa Cruz Biotechnology), nitrotyrosine (AB5411,
Millipore, USA), caveolin-1 (sc-824, Santa Cruz Biotechnol-
ogy), collagen type III (MU-167, Biogenex, USA), and ferritin
light chain (L-ferritin, sc-14420, Santa Cruz Biotechnology).
Staining was performed with a modi8ed avidin-biotin-
peroxidase complex and haematoxylin counterstaining as
described [25].
All histological stainings are expressed as percentage of
positive staining per area from 20 random images that were
viewed and evaluated independently by two investigators
who were blinded to sample identity.
2.7. Statistical Methods. Data are shown as mean ± standard
deviation (SD). Statistical analyses used absolute values and
GraphPad Prism 5.01 for Windows (GraphPad So_ware,
USA). Normally distributed parameters were compared
among groups usingANOVA. Parameterswith non-Gaussian
distribution (e.g., histological data) were compared using
Kruskal-Wallis test (nonparametric ANOVA) and Dunn’s
multiple comparison test.
3. Results
3.1. Model 1: DOX-Induced Cardiotoxicity in SHR-SP Rats on
Low Iron Diet (LID)
3.1.1. Anaemia and Iron Status. LID-fed rats developed IDA
as indicated by reduced Hb and TSAT (Groups D versus F;
푃 < 0.05; Table 1). In LID-fed rats treated with DOX, Hb
but not TSAT was further reduced compared to LID alone
(Groups A–C versus D; 푃 < 0.05). DOX-treated rats on ND
had lower Hb levels than untreated rats (Groups E versus F;
푃 < 0.05).
3.1.2. Cardiovascular Function. As previously described in
SHR-SP rats [26], systolic and diastolic blood pressure (SBP
and DBP) increased in all groups during the study, with
similar end of study values, except for lower values in LID-
fed rats (Groups D versus A–C, E, and F; 푃 < 0.01). Based
on echocardiography, LID-fed rats exhibited increased le_
ventricle dimensions (LVDD and LVSD) and decreased FS
compared to ND-fed rats (Groups D versus F; 푃 < 0.05;
Table 1). Lese cardiac alterations were aggravated by DOX
treatment in a dose-dependent fashion (Groups A–C and E
versus F; 푃 < 0.05). Similar trends were observed for the
marker of cardiac damage, caveolin-1.
3.1.3. Oxidative/Nitrosative Stress and Incammation. In the
heart of LID-fed rats (Group D), markers of oxidative stress
(Cu,Zn-SOD, GPx, and MDA), nitrosative stress (nitrotyro-
sine), and inXammation (TNF-훼) were signi8cantly elevated
compared to those of ND-fed animals (Group F; Table 1).
DOX treatment increased tissue levels of these markers in
LID-fed rats in a dose-dependent manner (Groups A–C)
compared to LID alone (Group D). As expected, the reduced
to oxidised glutathione ratio (GSH :GSSG ratio) followed an
inverse pattern.
3.1.4. Mortality. In contrast to LID alone, the combination
of LID and DOX resulted in a dose-dependent increase of
mortality in SHR-SP rats; 13%, 25%, and 50% for DOX doses
of 3, 4, and 5mg/kg, respectively.
3.2. Model 2: Modulation of DOX-Induced
Cardiotoxicity with FCM
3.2.1. Anaemia and Iron Status. Hb, serum iron, and TSAT
as well as L-ferritin in the heart were signi8cantly reduced
in LID-fed rats compared to ND-fed rats (Groups 6 versus
7; 푃 < 0.01; Table 2), and Hb was further decreased in rats
receiving DOX (Group 5; 푃 < 0.01). In DOX-treated, LID-
fed rats, all FCM regimens resulted in signi8cantly higher
Hb, serum iron, TSAT, and L-ferritin compared to saline
treatment (Groups 1–4 versus 5; 푃 < 0.01). Identical trends
were observed for L-ferritin immunostaining in the kidney
(Table S3). Comparing FCM regimens, a single dose of
concomitant or 3-day delayed FCM (15mg iron/kg) a_er the
second weekly DOX injection resulted in slightly higher Hb
levels at study end than 8ve weekly concomitant or delayed
FCM doses (each 3mg iron/kg; Groups 3 and 4 versus 1 and
2, respectively; 푃 < 0.05).
3.2.2. Blood Pressure and Echocardiography. Le increase in
mean blood pressure from baseline (SBP 160–167mmHg and
DBP93-94mmHg) to end of study (SBP 194–205mmHg and
DBP 120–123mmHg) was similar in all treatment groups.
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Table 2: Anaemia and iron status according to iron diet, DOX treatment, and supplementation with FCM.
Group
1 2 3 4 5 6 7 8
Treatment
Iron diet LID LID LID LID LID LID ND ND
DOX (4mg/kg BW) + + + + + − − +











Saline − − − − + + + −
Parameter
Hb (g/dL) 14.5 ± 0.5‡ 14.6 ± 0.3‡ 15.6 ± 0.4 15.5 ± 0.6 10.3 ± 0.3†§ 11.0 ± 0.3† 17.2 ± 0.7∗ 17.0 ± 0.7∗
Serum iron (휇g/dL) 214.3 ± 17.7 218.7 ± 15.8 221.8 ± 16.0 223.6 ± 15.0 117.1 ± 14.0† 121.0 ± 15.4 248.6 ± 16.6∗‖ 320.4 ± 19.5∗¶
TSAT (%) 36.2 ± 2.1 36.3 ± 2.3 36.2 ± 2.0 36.4 ± 2.1 19.2 ± 3.1† 20.0 ± 3.2 41.3 ± 2.1∗‖ 47.8 ± 2.4∗¶
L-Ferritin (%/area) 10.3 ± 1.6 10.5 ± 1.0 10.4 ± 1.1 10.7 ± 1.4 1.8 ± 0.4† 1.6 ± 0.3† 3.1 ± 0.5∗ 15.7 ± 1.9∗
Data presented as mean ± SD. LID: low iron diet; ND: normal diet; DOX: doxorubicin; FCM: ferric carboxymaltose; Hb: hemoglobin; TSAT: transferrin
saturation.
∗푃 < 0.05 for G7 and G8 versus G1, G2, G3, G4, G5, and G6; †푃 < 0.01 for G5 and G6 versus G1, G2, G3, and G4; ‡푃 < 0.05 for G1 and G2 versus G3 and G4;
§푃 < 0.01 for G5 versus G6; ‖푃 < 0.05 for G7 versus G1, G2, G3, and G4; ¶푃 < 0.01 for G8 versus G1, G2, G3, G4, and G7.
Echocardiography indicated that LID-fed rats had
increased LVDD, LVSD, and LV mass (LVM) and decreased
FS compared to ND-fed (Groups 6 versus 7; 푃 < 0.01;
Table 3). Addition of DOX to LID exacerbated all of these
cardiac abnormalities compared to LID alone (Groups 5
versus 6; 푃 < 0.01). In DOX-treated, LID-fed rats, FCM
signi8cantly improved these LV structural and functional
abnormalities compared to saline (Groups 1–4 versus 5;
푃 < 0.01). Among FCM regimens, LVSD improvements
were greater following a single FCM dose than 8ve weekly
FCM doses (Groups 3 and 4 versus 1 and 2; 푃 < 0.01).
Similarly, FCM treatment signi8cantly improved proteinuria
and urine NGAL levels (Table S1). Creatinine clearance was
not acected by DOX in LID-fed rats. Among FCM-treated
groups, NGAL levels were signi8cantly lower in rats given a
single FCM dose three days a_er DOX compared to other
FCM regimens (Groups 4 versus 1–3; 푃 < 0.01).
3.2.3. Oxidative/Nitrosative Stress and Incammation. Mark-
ers of oxidative stress (TBARS, Cu,Zn-SOD, GPx, and
GSH :GSSG ratio), nitrosative stress (nitrotyrosine and
iNOS), inXammation (TNF-훼 and IL-6), and 8brosis (colla-
gen III) in the heart were increased in LID-fed compared to
ND-fed rats (Groups 6 versus 7; 푃 < 0.01; Table 4; Figures
1 and 2). DOX treatment further increased these stress and
inXammation-related markers in LID-fed rats compared to
saline (Groups 5 versus 6; 푃 < 0.01). In DOX-treated, LID-
fed rats, FCM signi8cantly reduced oxidative stress (Groups
1–4 versus 5;푃 < 0.01). Among FCM treatments, signi8cantly
lower levels of oxidative stress were observed with a single
FCMdose compared to 8veweekly FCMdoses for allmarkers
except GPx (Groups 3 and 4 versus 1 and 2; 푃 < 0.01).
Similarly, oxidative/nitrosative stress and proinXammatory
markers in kidneys of LID-fed rats were increased compared
to ND-fed. Further increase by DOX treatment was at least
partly recovered by FCM treatment (Tables S2 and S3 and
Figures S1 and S2). As in the cardiac assessment, greater
reductions in renal oxidative stress markers were seen with
a single FCM dose compared to the repeated dosing (Groups
3 and 4 versus 1 and 2; 푃 < 0.01).
3.2.4. Histological Evaluation. Increased extracellular matrix
expansion and interstitial 8brosis was seen in LID-fed com-
pared to ND-fed rats (Groups 6 versus 7; Table 5). Le DOX-
associated further increase of 8brosis in LID-fed rats (Groups
5 versus 6; 푃 < 0.01) was largely normalized with all FCM
regimens (Groups 1–4 versus 5; 푃 < 0.01). Enlargement of
cardiomyocytes was observed in LID-fed compared to ND-
fed rats (Groups 6 versus 7) and was aggravated by DOX
(Groups 5 versus 6; 푃 < 0.01). All tested FCM treatments in
LID-fed rats signi8cantly improved cardiomyocyte and cap-
illary morphometric measures compared to saline (Groups
1–4 versus 5; 푃 < 0.01). In the kidney, histological assessment
showed similar trends (Table S3).
3.2.5. Edects of FCM Treatment in Iron-Replete Rats. ND-
fed rats treated with DOX and a single dose of FCM on
the same day as the second weekly DOX treatment (Group
8) had higher levels of serum iron and TSAT compared
to LID-fed rats given the same DOX and FCM treatments
(Group 3; Table 2). Also cardiac tissue L-ferritin levels as
well as cardiac oxidative/nitrosative stress, proinXammatory,
and 8brosis markers were increased (Tables 4 and 5; Figures
1 and 2), whereas cardiac function was reduced (Table 3).
Kidney assessments showed similar results, that is, higher
tissue L-ferritin levels (Table S3), as well as higher oxida-
tive/nitrosative stress, proinXammatory (Tables S2 and S3;
Figures S1 and S2), 8brosis (Table S3), and kidney damage
markers (Table S1).
3.2.6. Mortality. No deaths occurred in saline-treated, ND-
fed rats (Group 7) or any LID-fed group regardless of
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Table 3: Echocardiographic outcomes according to iron diet, DOX treatment, and supplementation with FCM.
Group
1 2 3 4 5 6 7 8
Parameter
LVDD (mm) 8.00 ± 0.09§ 8.01 ± 0.09§ 7.91 ± 0.10§§ 7.90 ± 0.10§§ 8.55 ± 0.11‡ 8.17 ± 0.08† 7.81 ± 0.10‖ 8.58 ± 0.11
LVSD (mm) 5.01 ± 0.08∗ 5.00 ± 0.09∗ 4.85 ± 0.09§ 4.80 ± 0.10§ 5.80 ± 0.10∗∗ 5.25 ± 0.08† 4.31 ± 0.11‖ 6.00 ± 0.10
LVPW (mm) 2.36 ± 0.10 2.33 ± 0.12 2.34 ± 0.11 2.33 ± 0.10 2.39 ± 0.12 2.36 ± 0.11 2.30 ± 0.12 2.29 ± 0.10
IVS (mm) 2.36 ± 0.10 2.36 ± 0.11 2.36 ± 0.09 2.36 ± 0.10 2.46 ± 0.11 2.39 ± 0.11 2.31 ± 0.10 2.30 ± 0.10
FS (%) 37.4 ± 0.5‖‖ 37.6 ± 0.5‖‖ 38.7 ± 0.6§ 39.2 ± 0.9§ 32.2 ± 1.0∗∗ 35.7 ± 0.6† 44.8 ± 1.1‖ 30.1 ± 1.3
LVM (g) 1.33 ± 0.06¶ 1.31 ± 0.07‡‡ 1.28 ± 0.09‡‡ 1.25 ± 0.08‡‡ 1.48 ± 0.06∗∗ 1.36 ± 0.06†† 1.20 ± 0.07‖ 1.32 ± 0.08
Data presented as mean ± SD. A brief tabular overview of treatments in Groups 1–8 is included in Table 2. Further details are described in the Materials and
Methods section. LID: low iron diet; ND: normal diet; DOX: doxorubicin; FCM: ferric carboxymaltose; LVDD: le_ ventricular end-diastolic diameter; LVSD:
le_ ventricular end-systolic diameter; LVPW: le_ ventricular posterior wall thickness; IVS: interventricular septum thickness; FS: fractional shortening; LVM:
le_ ventricular mass.
∗푃 < 0.01 versus G3 to G8; †푃 < 0.01 versus G7 and G8; ‡푃 < 0.01 versus G6 and G7; §푃 < 0.01 versus G5 to G8; ‖푃 < 0.01 versus G8; ¶푃 < 0.01 versus G5
and G7; ∗∗푃 < 0.01 versus G6 to G8; ††푃 < 0.01 versus G7; ‡‡푃 < 0.01 versus G5; §§푃 < 0.01 versus G5, G6, and G8; ‖‖푃 < 0.01 versus G4 to G8.
Table 4: Cardiac oxidative/nitrosative stress and inXammation according to iron diet, DOX treatment, and supplementation with FCM.
Group
1 2 3 4 5 6 7 8
Parameter
MDA (nmol/mg protein) 3.6 ± 0.2∗∗ 3.5 ± 0.3∗∗ 2.9 ± 0.1†† 2.7 ± 0.2∗ 4.3 ± 0.2‡‡ 2.5 ± 0.2§§ 1.8 ± 0.2‖ 5.7 ± 0.3
Cu,Zn-SOD (U/mg protein) 36.9 ± 3.2∗∗ 34.9 ± 2.0∗∗ 30.4 ± 2.1†† 27.3 ± 3.0∗ 42.3 ± 2.4‡‡ 26.3 ± 2.1§§ 16.0 ± 1.8‖ 49.2 ± 3.3
GPx (U/mg protein) 409 ± 24∗∗ 399 ± 20‡‡ 360 ± 20†† 353 ± 23∗ 459 ± 24‡‡ 320 ± 24§§ 256 ± 21‖ 507 ± 32
GSH :GSSG ratio 2.5 ± 0.2∗∗ 2.6 ± 0.1∗∗ 3.6 ± 0.2†† 3.8 ± 0.2∗ 2.4 ± 0.2‡‡ 3.9 ± 0.1§§ 4.8 ± 0.2‖ 2.0 ± 0.2
Nitrotyrosine (%/area) 18.0 ± 3.3 17.1 ± 2.6 16.9 ± 3.1 16.1 ± 2.2∗ 29.1 ± 3.4‡ 16.8 ± 3.8 11.6 ± 1.3† 34.5 ± 4.5‡
iNOS (%/area) 6.9 ± 1.0 6.4 ± 1.1 6.7 ± 0.8 6.5 ± 0.9 21.4 ± 1.7‡ 2.5 ± 0.4† 2.3 ± 0.6† 20.3 ± 2.0‡
TNF-훼 (%/area) 15.1 ± 1.4 14.4 ± 1.5 14.2 ± 1.2 14.1 ± 1.3 19.6 ± 1.4‡ 15.0 ± 1.5 11.9 ± 1.1§ 23.6 ± 2.0§
IL-6 (%/area) 15.7 ± 2.2 14.6 ± 1.7 15.2 ± 1.4 14.4 ± 1.6 28.4 ± 2.5‡ 20.3 ± 1.6† 3.6 ± 1.0§ 34.9 ± 3.1§
Collagen III (%/area) 7.4 ± 1.0 7.5 ± 0.9 7.3 ± 1.1 6.6 ± 0.9 13.0 ± 1.5¶ 7.0 ± 1.1 4.3 ± 0.7§ 13.9 ± 1.9¶
Data presented as mean ± SD. A brief tabular overview of treatments in Groups 1–8 is included in Table 2. Further details are described in the
Materials and Methods section. MDA: malondialdehyde; Cu,Zn-SOD: copper-zinc superoxide dismutase; GPx: glutathione peroxidase; GSH :GSSG: reduced
glutathione : oxidised glutathione; iNOS: inducible nitric oxide synthase; TNF-훼: tumour necrosis factor-alpha; IL-6: interleukin-6.
∗푃 < 0.01 versus G5, G7, and G8; †푃 < 0.01 versus G1, G2, G3, and G4; ‡푃 < 0.01 versus G1, G2, G3, G4, G6, and G7; §푃 < 0.01 versus all groups; ‖푃 < 0.01
versus G8; ¶푃 < 0.01 versus G1, G2, G3, G4, and G6; ∗∗푃 < 0.01 versus G3 to G8; ††푃 < 0.01 versus G5 to G8; ‡‡푃 < 0.01 versus G6 to G8; §§푃 < 0.01 versus
G7, G8.
Table 5: Histomorphometric assessment of the heart according to iron diet, DOX treatment, and supplementation with FCM.
Group
1 2 3 4 5 6 7 8
Parameter
Masson’s trichrome (% area) 13.7 ± 1.1∗ 14.3 ± 1.4∗ 13.0 ± 1.2∗ 12.1 ± 1.4∗ 17.4 ± 0.9‡ 11.7 ± 1.8‖ 8.1 ± 1.2¶ 20.9 ± 1.2
Sirius Red (% area) 10.3 ± 1.1∗ 9.9 ± 1.4∗ 9.8 ± 1.3∗ 9.3 ± 1.1∗ 15.9 ± 1.1‡ 11.0 ± 1.2‖ 7.8 ± 1.3¶ 19.3 ± 1.8
Cardiomyocyte width (휇m) 31.7 ± 1.1† 31.3 ± 1.2† 31.6 ± 1.1† 31.0 ± 1.0† 35.2 ± 0.9‡ 33.4 ± 0.4‖ 31.1 ± 0.9† 31.4 ± 0.9†
Cardiomyocyte density (푛/area) 26.7 ± 0.8† 27.1 ± 1.0† 26.8 ± 0.8† 27.2 ± 0.8† 20.1 ± 1.6§ 25.2 ± 0.7 27.1 ± 0.7† 26.9 ± 0.8†
Capillary density (푛/area) 18.5 ± 0.7† 19.0 ± 1.0† 18.8 ± 0.9† 19.1 ± 0.7† 12.3 ± 1.1§ 17.1 ± 1.0 19.1 ± 1.3 18.9 ± 1.1
Cardiomyocyte/capillary ratio 0.71 ± 0.03† 0.71 ± 0.03† 0.70 ± 0.02† 0.70 ± 0.03† 0.61 ± 0.01§ 0.67 ± 0.03 0.71 ± 0.03† 0.70 ± 0.04†
Data presented as mean ± SD. A brief tabular overview of treatments in Groups 1–8 is included in Table 2. Further details are described in the Materials and
Methods Section.
∗푃 < 0.01 versus G5, G6, G7, and G8; †푃 < 0.01 versus G5 and G6; ‡푃 < 0.01 versus G6, G7, and G8; §푃 < 0.01 versus G6; ‖푃 < 0.01 versus G7 and G8;
¶푃 < 0.01 versus G8.
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Figure 1: Immunohistochemical detection of nitrosative stress in the heart. Light micrographs of heart sections from rats treated as outlined
inMaterials andMethods Section andTable 2. In LID-fed rats (Groups 1–6 (G1–G6)), DOX treatment (G5) increased positive immunostaining
(arrows) for nitrotyrosine and inducible nitric oxide synthase (iNOS) compared to saline treatment (G6), whereas FCM administration to
DOX-treated rats (G1–G4) reduced levels of nitrotyrosine and iNOS compared to DOX treatment alone (G5). In ND-fed rats (G7 and G8),
treatment with DOX and FCM (G8) greatly increased positive immunostaining compared to ND alone (G7). (a) Original magni8cation,
×400. (b) Original magni8cation, ×200.
treatment (Groups 1–6). Deathswere reported for two of eight
ND-fed rats treated with concomitant DOX and FCM (15mg
iron/kg) (Group 8).
4. Discussion
Le data presented herein show that FCM at a total dose
of 15mg iron/kg BW resolves IDA and attenuates IDA-
and DOX-associated cardiorenal toxicity in SHR-SP rats. In
line with prior clinical and nonclinical studies, IDA alone
increased cardiac and renal oxidative/nitrosative stress and
inXammation as well as abnormalities in cardiac morphology
and function in the models described here [13, 27–29]. DOX
treatment further increased oxidative/nitrosative stress and
inXammation and exacerbated cardiorenal toxicity, whereas
supplementation with FCM signi8cantly improved these
parameters.
Ledevelopment of hypertension in SHR-SP rats [26]was
not acected by LID, DOX treatment, or combined treatment
with DOX and FCM.
Bene8cial ecects of FCM were observed whether admin-
istered as a single dose or as repeated 3mg/kg doses; yet single
dose administration was associated with a trend towards
higher Hb as well as less oxidative stress, LVSD, and urinary
NGAL (an early marker of acute kidney damage) [30]. Also
administration of FCM either concurrent with or three days
a_er DOX treatment was equally ecective. Le investigated
regimens reXect the clinical setting in terms of total dose
infusion and possible treatment schedules in DOX-treated
patients.
Anthracycline-mediated production of ROS is consid-
ered an important mechanism of AIC, and iron loading has
been suggested to potentiate this mechanism [31]. Lerefore,
there are concerns that concomitant administration of iron
and anthracyclines could exacerbate AIC [9]. However, FCM
did not increase AIC in this model. Moreover, the correction
of IDA with FCM markedly attenuated AIC. Lere are
interesting parallels between the pathological features of IDA-
and DOX-associated cardiotoxicity, including le_ ventricular
dilatation and hypertrophy that can progress to heart failure
[2, 24, 27]. While the pathogenic mechanisms leading to
these characteristic LV changes may dicer between IDA and
DOX treatment, it is noteworthy that perturbation of iron
metabolism and elevation of oxidative stress/inXammation
is common in both [32, 33]. Lerefore, clinical data in
iron-de8cient chronic heart failure (CHF) patients showing
that FCM improved functional status, quality of life, and
exercise capacity [27, 34] are in line with the FCM-based
improvement of IDA- andDOX-associated stress and cardiac
impairment in SHR-SP rats.
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Figure 2: Immunohistochemical detection of inXammation in the heart. Light micrographs of heart sections from rats treated as outlined in
Materials and Methods Section and Table 2. In LID-fed rats (Groups 1–6 (G1–G6)), DOX treatment (G5) increased positive immunostaining
(arrows) for interleukin-6 (IL-6) and tumour necrosis factor-훼 (TNF-훼) compared to saline treatment (G6), whereas FCM administration
to DOX-treated rats (G1–G4) reduced levels of IL-6 and TNF-훼 compared to DOX treatment alone (G5). For IL-6, FCM treatment reduced
staining levels below that of LID alone (G6). In ND-fed rats (G7 and G8), treatment with DOX and FCM (G8) greatly increased positive
immunostaining compared to ND alone (G7). (a) and (b) original magni8cation, ×400.
In rodents, DOX-induced cardiotoxicity is increased by
dietary and genetic iron overload [35, 36]. In the present
study, combined treatment of iron-replete (ND-fed) SHR-SP
rats with DOX and i.v. iron markedly increased cardiorenal
toxicity. Although the relative contributions of the two treat-
ments cannot be determined in our study, we hypothesise
that excessive levels of systemic iron can exacerbate the
cardiorenal toxicity of DOX [37, 38].
Notably, AIC can occur as “acute” cardiotoxicity within
hours or days of treatment as well as early-onset or late-
onset AIC within one year or a_er one year of treatment,
respectively [2]. Acute AIC o_en presents as disturbances in
intracardiac conduction and arrhythmias, whereas early- and
late-onset cardiotoxicity are associated with LV dysfunction
and can lead to heart failure. Our model system investigated
the modulation of acute AIC and showed that, in iron-
de8cient hypertensive rats, concomitant i.v. iron canmaintain
normal contractility of the heart. Whether the reduction or
prevention of acute AIC has also a positive inXuence on early-
or late-onset AIC has to be investigated in a model with a
longer follow-up period.
Since this study focused on the characterisation of DOX-
induced cardiotoxicity and its modulation with i.v. iron, rats
were nontumour bearing. However, comorbid hypertension
was addressed by using SHR-SP rats. Dietary iron restric-
tion resulted in IDA as well as signi8cant oxidative stress
and inXammation, which were aggravated by DOX. Le
decrease inHb associated withDOX alone suggests that iron-
independent ecects on erythropoiesis, possibly mediated by
oxidative stress and inXammation, are also addressed in this
model. Hence, the model combines features of IDA and
chemotherapy-induced anaemia. Nevertheless, the results of
this study are based on a model of absolute iron de8ciency
and should not be extrapolated to patients with functional
iron de8ciency since the biodistribution and erythropoietic
evcacy of i.v. iron may be dicerent in the clinical setting of
cancer-associated anaemia.
5. Conclusion
FCM did not aggravate DOX-induced cardiotoxicity in iron-
de8cient hypertensive rats receiving chronic DOX treatment.
Moreover, administration of FCM attenuated cardiorenal
oxidative/nitrosative stress, inXammation, and 8brosis as well
as ecects on cardiac and renal morphology and function
compared to saline controls.
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